Cosentyx sales set to grow after approval in sixth indication

Swiss pharma major Novartis (NOVN: VX) has secured another approval from the US regulator for Cosentyx (secukinumab), a biologic which blocks the interleukin (IL)-17A cytokine.

The label update, which has been made based on analyses from the Phase III SUNSHINE and SUNRISE trials, enables marketing for moderate to severe hidradenitis suppurativa (HS).

HS is a chronic, systemic and often painful skin disease that causes recurring boil-like lumps which can result in irreversible scarring.